Banking on the future of regenerative medicine with cGMP-compliant iPSC lines
Melissa K. Carpenter
Abstract
Melissa K. Carpenter
Abstract
The ability to generate cell therapies from pluripotent stem cells is changing the way we think about diseases and how to treat them. Regenerative medicines derived from pluripotent stem cells have the potential to treat a large number of diseases, many of which currently lack efficacious therapies, by identifying the deficient or non-functional cell type involved in the disease and generating the corresponding healthy cell type from pluripotent stem cells. However, like other cell and gene therapy products, pluripotent stem cell-based regenerative medicines face development challenges that must be solved before we can deliver on their promise to patients.
A significance statement is not available in the OpenAlex record.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
The ability to generate cell therapies from pluripotent stem cells is changing the way we think about diseases and how to treat them. Regenerative medicines derived from pluripotent stem cells have the potential to treat a large number of diseases, many of which currently lack efficacious therapies, by identifying the deficient or non-functional cell type involved in the disease and generating the corresponding healthy cell type from pluripotent stem cells. However, like other cell and gene therapy products, pluripotent stem cell-based regenerative medicines face development challenges that must be solved before we can deliver on their promise to patients.
Key concepts: Induced pluripotent stem cell, Regenerative medicine, Stem cell, Embryonic stem cell, Cell therapy, Cell type, Neuroscience, Cell